Chip stocks fall with Nvidia after data center rev disappointment
On Tuesday, H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to InvestingPro data, analyst targets range from $5.50 to $18.00, with the stock currently trading below its Fair Value. The firm’s endorsement comes in the wake of Vanda’s announcement regarding a significant licensing agreement. Vanda disclosed on Monday that it had entered into an exclusive, global license agreement with AnaptysBio (NASDAQ:ANAB) for the monoclonal antibody imsidolimab, an IL-36R antagonist. The company’s strong financial position, with more cash than debt and an impressive gross profit margin of 93.62%, suggests it has the resources to support this strategic initiative.
Imsidolimab has shown promise in treating generalized pustular psoriasis (GPP), a rare and severe skin condition often linked to genetic mutations. The antibody has completed two critical Phase 3 trials, GEMINI-1 and GEMINI-2, which assessed its safety and efficacy. By inhibiting the IL-36 receptor, imsidolimab aims to correct the regulatory imbalance in patients with GPP, thereby reducing chronic skin inflammation and associated systemic symptoms.
The successful conclusion of the development program for imsidolimab in GPP sets the stage for Vanda to begin the technology transfer activities and the preparation of regulatory submissions. The company plans to initiate and complete these activities in 2025, with the goal of submitting Biologics License Application (BLA) and Marketing Authorization Application (MAA) in the U.S. and EU, respectively.
H.C. Wainwright’s reiteration of the Buy rating reflects a positive outlook on Vanda’s strategic business development. The firm awaits further details on the timeline for imsidolimab’s market entry in the U.S. before incorporating the treatment into their valuation assessment. The current valuation is deemed conservative by the firm, given the positive results from the pivotal trials of imsidolimab. InvestingPro analysis shows the company maintains a healthy current ratio of 4.85, and analysts expect profitability this year. For deeper insights into Vanda’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Vanda Pharmaceuticals has seen a flurry of activities. The pharmaceutical company reported mixed results for Q3 2024, with revenues slightly dipping to $145.6 million from the previous year’s $147.4 million due to generic competition affecting Hetlioz sales. However, PONVORY sales reached $21.3 million following its acquisition, contributing to the company’s revenue stream. Despite a net loss of $14 million for the first nine months of 2024, Vanda Pharmaceuticals adjusted its 2024 guidance upwards, projecting total net product sales of $190 million to $210 million.
In addition to financial changes, Vanda Pharmaceuticals has been active in its pursuit of new developments. The company submitted a new drug application to the U.S. Food and Drug Administration (FDA) for tradipitant, a potential treatment for motion sickness. This move is part of Vanda’s strategy to counter challenges and drive growth through new product launches.
On the analyst front, H.C. Wainwright reaffirmed their positive stance on Vanda Pharmaceuticals with a Buy rating and a price target of $18.00, indicating confidence in the company’s potential. The firm highlighted recent developments regarding Vanda’s New Drug Application (NDA) for tradipitant. These are recent developments investors should be aware of.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.